| European Federation of Internal Medicine

Appendix 1: Acceptable intakes established for N-nitrosamines

Submitted by Anonymous (not verified) on 5 February 2025 - 9:04

Appendix 1: Acceptable intakes established for N-nitrosamines

Read more about Appendix 1: Acceptable intakes established for N-nitrosamines

Human medicines European public assessment report (EPAR): Jalra, vildagliptin, Date of authorisation: 19/11/2008, Revision: 25, Status: Authorised

Submitted by Anonymous (not verified) on 5 February 2025 - 8:28

Human medicines European public assessment report (EPAR): Jalra, vildagliptin, Date of authorisation: 19/11/2008, Revision: 25, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Jalra, vildagliptin, Date of authorisation: 19/11/2008, Revision: 25, Status: Authorised

Human medicines European public assessment report (EPAR): Repaglinide Krka, repaglinide, Date of authorisation: 03/11/2009, Revision: 9, Status: Authorised

Submitted by Anonymous (not verified) on 4 February 2025 - 15:52

Human medicines European public assessment report (EPAR): Repaglinide Krka, repaglinide, Date of authorisation: 03/11/2009, Revision: 9, Status: Authorised

Read more about Human medicines European public assessment report (EPAR): Repaglinide Krka, repaglinide, Date of authorisation: 03/11/2009, Revision: 9, Status: Authorised

Questions and answers clinic on post-authorisation procedure management in IRIS, Online, from 8 January 2025, 14:00 (CET) to 8 January 2025, 15:00 (CET)

Submitted by Anonymous (not verified) on 4 February 2025 - 15:23

Questions and answers clinic on post-authorisation procedure management in IRIS, Online, from 8 January 2025, 14:00 (CET) to 8 January 2025, 15:00 (CET)